Maria Τektonidou/LinkedIn
Apr 2, 2026, 14:39
Maria Τektonidou: STAT1 as a Potential Therapeutic Target in Thrombotic Antiphospholipid Syndrome
Maria Τektonidou, Professor of Rheumatology at National and Kapodistrian University of Athens, shared a post on LinkedIn, about a recent article she and her colleagues co-authored, adding:
“Gene co-expression and drug-gene interaction analysis reveal STAT1 as a potential therapeutic target in thrombotic antiphospholipid syndrome”
Title: RNA sequencing-derived gene co-expression and drug-gene interaction analysis reveal STAT1 as a potential therapeutic target in thrombotic antiphospholipid syndrome
Authors: Michail Baltsiotis, Kleio-Maria Verrou, Petros P Sfikakis, Maria G Tektonidou
Read the Full Article on Frontiers in Immunology
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 3, 2026, 13:51Ton Lisman: ISTH Opens Applications for Leadership Roles in Liver Disease Research
-
Jun 3, 2026, 13:41Abhishek Jain: New Microphysiological Model Sheds Light on COVID-19 Vascular Complications
-
Jun 3, 2026, 13:26M Shujat Rasool: DVT Red Flags Every Clinician Should Know
-
Jun 3, 2026, 09:14Wolfgang Miesbach: How Should We Monitor FVIII Expression After AAV5-Based Gene Therapy?
-
Jun 3, 2026, 09:02June Giddings: Giddings Strong Foundation Website Is Now Live
-
Jun 3, 2026, 08:47Alba Grayston Morales: How IL-1 Signaling Drives Injury and Repair in The Ischaemic Brain
-
Jun 3, 2026, 08:32Rob Maloney: Over 104,000 USD Raised at The 2026 Trot to Clot
-
Jun 3, 2026, 08:27Leonard Valentino: Why Clear Communication Matters in the Era of Gene Editing
-
Jun 3, 2026, 08:15Wolfgang Miesbach: When to Stop Anticoagulation after AF Ablation in 2026?